Cost‐Effectiveness Analysis of Second‐Line Chemotherapy Agents for Advanced Gastric Cancer

Abstract

Gastric cancer is the fifth most common malignancy and second leading cause of cancer‐related mortality. Chemotherapy options for patients who fail first‐line treatment are limited. Thus the objective of this study was to assess the cost‐effectiveness of second‐line treatment options for patients with advanced or metastatic gastric cancer.